ERBB2 and mismatch repair cancer syndrome 1: Additionally, for GC patients with MSI-high or MMR deficiency, neoadjuvant treatment with ipilimumab plus nivolumab has been recommended (25); while the percentage of MSI-high or MMR deficiency status in HER2-positive GC is relatively low.